<DOC>
	<DOCNO>NCT00881816</DOCNO>
	<brief_summary>The purpose study determine maximum tolerate dose dose limit toxicity liposomal paclitaxel plus capecitabine Chinese patient advance gastric carcinoma .</brief_summary>
	<brief_title>Dose Escalation Study Liposomal Paclitaxel Plus Capecitabine Chinese Patients With Advanced Gastric Carcinoma</brief_title>
	<detailed_description>There clinical trial show taxane optional treatment gastric cancer . Liposomal paclitaxel different pharmacokinetic feature compare conventional taxane . This study design find maximum tolerate dose dose limit toxicity liposomal paclitaxel combine capecitabine Chinese patient advance gastric carcinoma .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Age : 18 75 Histologically cytologically document gastric adenocarcinoma esophagusgastro adenocarcinoma metastatic advanced stage with/without measurable tumor accord RECIST standard Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 01 Patients expect live least 3 month No prior systemic chemotherapy advance stereo tumor recruitment ( recidivist/ metastatic without perioperative chemotherapy least 6m ) No Previous anaphylactic reaction hormone Obtaining inform consent Patients may comply study protocol Laboratory test : Absolute neutrophil count ( ANC ) ≥2,000/mm³ , Platelet count ≥100,000/mm³ , Hemoglobin ≥9.0 g/dL , Serum creatinine≤1.5 x institutional upper limit normal ( ULN ) , Creatinine clearance≥50ml/min，Total bilirubin≤1.5 x institutional upper limit normal ( ULN ) , Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤1.5 x ULN . In case know liver metastasis , ALT AST（SGOT） ≤1.5 x ULN . Active uncontrolled central nervous system metastasis No adequate organ function know disease : myocardial infarction active heart disease neuropathy mental disease include dementia epilepsy blind、deaf、dumb extremity disability know infection active diffuse intravascular coagulation know infection hepatitis virus Pregnant nursing , fertile patient would use effective contraception study treatment Prior clinically significant gastrointestinal tract disease , would influence obviously capecitabine absorb , include ability swallow attend physician No active malignancy except complete remission squamous cell carcinoma situ cervix anus , completely resect basal cell carcinoma , recrudescence least 2 year time response first document Having study medication within 4w Having radiation therapy operation within 4w Any nonremission toxicity ≥ CTC 1 prior anticancer therapy ( include radiation therapy ) ( except alopecie hemoglobin ) Peripheral nerve disease ≥ 2 Previous anaphylactic reaction Capecitabine Paclitaxel diluent base Absence dihydropyrimidine dehydrogenase Patients suitable determine attend physician .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Liposomal Paclitaxel</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>Maximum tolerate dose</keyword>
	<keyword>Dose limit toxicity</keyword>
</DOC>